Kite Pharma, Inc. Insider Trading for June 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for June 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 285,394 | |
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 295,394 | |
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 50.15 | 10,000 | 501,484 | 95,401 | 105.4 K to 95.4 K (-9.49 %) |
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 105,401 | 95.4 K to 105.4 K (+10.48 %) |
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 51.28 | 10,000 | 512,754 | 95,401 | 105.4 K to 95.4 K (-9.49 %) |
| Jun 27 2016 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 105,401 | 95.4 K to 105.4 K (+10.48 %) |
| Jun 08 2016 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 58.38 | 4,000 | 233,516 | 27,865 | 31.9 K to 27.9 K (-12.55 %) |
| Jun 08 2016 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 57.56 | 5,000 | 287,805 | 131,017 | 136 K to 131 K (-3.68 %) |
| Jun 08 2016 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 58.25 | 5,000 | 291,260 | 136,017 | 141 K to 136 K (-3.55 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Grant | A | 0.00 | 1,950 | 0 | 21,616 | 19.7 K to 21.6 K (+9.92 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Grant | A | 0.00 | 1,950 | 0 | 4,021 | 2.1 K to 4 K (+94.16 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Grant | A | 0.00 | 1,950 | 0 | 67,964 | 66 K to 68 K (+2.95 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Grant | A | 0.00 | 1,950 | 0 | 141,017 | 139.1 K to 141 K (+1.40 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Grant | A | 0.00 | 1,950 | 0 | 1,950 | 0 to 2 K |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Grant | A | 0.00 | 1,950 | 0 | 216,950 | 215 K to 217 K (+0.91 %) |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Grant | A | 0.00 | 1,950 | 0 | 1,950 | 0 to 2 K |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Grant | A | 0.00 | 1,950 | 0 | 87,988 | 86 K to 88 K (+2.27 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,500 | 10,335 | 83,708 | |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 1,500 | 10,335 | 85,208 | |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 51.90 | 175 | 9,083 | 14,867 | 15 K to 14.9 K (-1.16 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 51.22 | 1,325 | 67,867 | 15,042 | 16.4 K to 15 K (-8.10 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 1,500 | 10,335 | 16,367 | 14.9 K to 16.4 K (+10.09 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 50.00 | 1,500 | 75,000 | 14,867 | 16.4 K to 14.9 K (-9.16 %) |
| Jun 02 2016 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 1,500 | 10,335 | 16,367 | 14.9 K to 16.4 K (+10.09 %) |